Lynparza and Imfinzi substantially increased the average response time, outperforming chemotherapy, in providing clinical advantages for individuals with advanced or relapsed endometrial cancer that shows proficient DNA mismatch repair.

Intellia Therapeutics has revealed the initiation of their Phase 3 clinical trial named MAGNITUDE, where the first participant received a one-time CRISPR therapy, NTLA-2001, aimed at treating cardiac amyloidosis caused by transthyretin.

During the 2024 ACS Spring Meeting, Brenig Therapeutics showcased novel findings related to their leading LRRK2 inhibitor, which is aimed at tackling Parkinson's disease.

Citius Pharmaceuticals Reveals the U.S. FDA's Approval of a Revised BLA for LYMPHIR™ (Denileukin Diftitox), Aimed at Treating Reoccuring or Treatment-Resistant Cutaneous T-Cell Lymphoma in Adults.

Shanghai Henlius Biotech, Inc. has reported the commencement of a phase 1 clinical study for HLX42, by administering the initial dose to a participant.

Formycon and Fresenius Kabi have concluded a resolution for their biosimilar contender FYB202, based on ustekinumab, targeting markets in Europe and Canada.

KeChow Pharma announces that its drug Tunlametinib (HL-085) has been approved by the NMPA, becoming the first targeted therapy approved for the treatment of NRAS-mutant advanced melanoma patients who have been previously treated with PD-1/PD-L1 therapy.

Shaperon has initiated enrollment of its inaugural participant in the second-stage American clinical study for its eczema treatment, branded as Nugel.

Promising phase III results for RUBY suggest expanded use of Jemperli (dostarlimab-gxly) paired with other treatments in cases of initial severe or returning uterine cancer.

AstraZeneca plans to purchase Amolyt Pharma, thereby broadening its advanced portfolio in uncommon disorders.

Lirum BioMed Reveals Encouraging Results for Its Innovative Treatment LX-101, Showing Strong Early-Phase Effectiveness in Tackling IGF-Linked Tumors, Scheduled for Discussion at the 2024 ESMO Congress on Sarcoma and Uncommon Cancers.

Nuvectis Pharma Releases Promising Initial Results from Early-Stage NXP800 Study in Platinum-Resilient Ovarian Cancer with ARID1a Alterations.